← All trials
NCT02655419
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2016
- Primary completion
- Nov 24, 2017
- Completion date
- Nov 24, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- University of LimogesCollaborator
- University of SevilleOverall official - principal investigator
- University of CologneOverall official - principal investigator
- Servicio Andaluz de Salud, SpainCollaborator
- University of CologneCollaborator
- Utrecht UniversityCollaborator
- University of LimogesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.